Effects of iron-based phosphate binders on mortality and cardiovascular events in patients receiving maintenance dialysis [PDF]
Scientific Reports, 2023 Phosphate binders are the main treatment for hyperphosphatemia in patients with chronic kidney disease, and iron-based phosphate binders have been used with increasing frequency in recent years.
Akihito Tanaka +5 more
doaj +2 more sources
Phosphate binders affect vitamin K concentration by undesired binding, an in vitro study [PDF]
BMC Nephrology, 2017 Background Vascular calcification is a major contributing factor to mortality in end stage renal disease (ESRD). Despite the efficacy of phosphate binders to improve hyperphosphatemia, data on vascular calcification are less clear.
A. Neradova +5 more
doaj +2 more sources
Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide [PDF]
International Journal of Nephrology and Renovascular Disease, 2016 Valeria Cernaro, Domenico Santoro, Antonio Lacquaniti, Giuseppe Costantino, Luca Visconti, Antoine Buemi, Michele Buemi Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy Abstract: Chronic kidney disease-mineral bone ...
Cernaro V +6 more
doaj +2 more sources
A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study [PDF]
BMC Nephrology, 2019 Background Approximately 30% of patients on dialysis received combination therapy for their phosphate binder prescription; however, few studies for combined effects of phosphate binders are reported.
Atsushi Yaguchi +7 more
doaj +2 more sources
Use of phosphate binders in end-stage renal disease: An experience from a secondary care hospital in United Arab Emirates [PDF]
Journal of Pharmacy and Bioallied Sciences, 2019 Objective: Hyperphosphatemia in end-stage renal disease (ESRD) is associated with many serious patient-level consequences including cardiovascular events and mortality.
Syed Arman Rabbani +4 more
doaj +2 more sources
Iron-based phosphate binders: do they offer advantages over currently available phosphate binders? [PDF]
CKJ: Clinical Kidney Journal, 2015 Pablo A Ureña-Torres +1 more
exaly +2 more sources
Phosphate Absorption and Hyperphosphatemia Management in Kidney Disease: A Physiology-Based Review
Kidney Medicine, 2021 Phosphate absorption occurs in the gastrointestinal tract through paracellular absorption and transcellular transport. The paracellular pathway does not saturate and has a significantly higher absorption capacity than does the transcellular pathway ...
Steven N. Fishbane, Sagar Nigwekar
doaj +1 more source
The Impact of Phosphorus Management Today on Quality of Life: Patient Perspectives
Kidney Medicine, 2022 Patients with kidney failure and early stages of chronic kidney disease often develop hyperphosphatemia, which is associated with negative outcomes. The reduction of phosphate levels is the established clinical practice.
Derek Forfang +2 more
doaj +1 more source
In Search of an Efficient Complexing Agent for Oxalates and Phosphates: A Quantum Chemical Study
Nanomaterials, 2021 Limiting gastrointestinal oxalate absorption is a promising approach to reduce urinary oxalate excretion in patients with idiopathic and enteric hyperoxaluria.
Jelle Vekeman +9 more
doaj +1 more source
Tailored synbiotic powder (functional food) to prevent hyperphosphataemia (kidney disorder)
Scientific Reports, 2021 Hyperphosphataemia is treated with phosphate binders, which can cause adverse effects. Spray-dried synbiotic powder (SP) composed of Lactobacillus casei JCM1134 (a phosphate-accumulating organism; PAO) and Aloe vera is potentially a safer alternative for
Ajeeta Anand +2 more
doaj +1 more source